• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by ACADIA Pharmaceuticals Inc. (Amendment)

    2/13/24 4:56:01 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACAD alert in real time by email
    SC 13G/A 1 tv0169-acadiapharmaceuticals.htm SCHEDULE 13G/A acadiapharmaceuticalsinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 8)*

    Name of issuer:  ACADIA Pharmaceuticals Inc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  004225108

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  004225108

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    220,637

    7.  SOLE DISPOSITIVE POWER

    13,055,348

    8.  SHARED DISPOSITIVE POWER

    340,661

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    13,396,009

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    8.16%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    ACADIA Pharmaceuticals Inc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    12830 El Camino Real, Suite 400
    San Diego, CA 92130-3331

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    004225108

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $ACAD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACAD

    DatePrice TargetRatingAnalyst
    5/21/2025$35.00Hold → Buy
    Deutsche Bank
    2/11/2025$22.00Hold
    Deutsche Bank
    1/3/2025$23.00 → $20.00Buy → Neutral
    Guggenheim
    10/10/2024Mkt Perform
    Raymond James
    8/7/2024$28.00 → $20.00Overweight → Equal-Weight
    Morgan Stanley
    6/27/2024$31.00Outperform
    BMO Capital Markets
    3/12/2024$36.00 → $32.00Buy
    Needham
    3/12/2024$39.00 → $25.00Buy → Neutral
    Mizuho
    More analyst ratings

    $ACAD
    Financials

    Live finance-specific insights

    See more
    • Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview

      - First quarter total revenues of $244.3 million, up 19% year-over-year - First quarter NUPLAZID® (pimavanserin) net product sales of $159.7 million, up 23% year-over-year - First quarter DAYBUE® (trofinetide) net product sales of $84.6 million, up 11% year-over-year, and up 9.5% in unique patients shipped - Reiterates full year 2025 revenue guidance including DAYBUE net sales of $380 to $405 million and NUPLAZID net sales of $650 to $690 million - Accelerated timing for COMPASS PWS Phase 3 study of ACP-101 in Prader Willi Syndrome, topline results now expected in early Q4 2025 Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced its financial results for the first quarter ended M

      5/7/25 4:05:00 PM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025

      Company to host conference call and webcast on Wednesday, May 7, 2025, at 4:30 p.m. Eastern Time Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will report first quarter financial results on Wednesday, May 7, 2025, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on May 7, 2025, at 4:30 p.m. Eastern Time. The webcast will be available on Acadia's website, Acadia.com under the investors section and will be archived there until August 6, 2025. The conference call may also be accessed by registering for the call here. Once registered, participants will receive an email with the dial-in number and unique PI

      4/23/25 4:05:00 PM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

      - 2024 total net product sales of $957.8 million, reflecting 32% revenue growth - Fourth quarter DAYBUE® (trofinetide) net product sales of $96.7 million and full year 2024 net product sales of $348.4 million - Fourth quarter NUPLAZID® (pimavanserin) net product sales of $162.9 million and full year 2024 net product sales of $609.4 million - Full year 2025 total revenue guidance of $1.03 to $1.095 billion including DAYBUE net sales guidance of $380 to $405 million and NUPLAZID net sales guidance of $650 to $690 million Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced its financial results for the fourth quarter and full year ended December 31, 2024. "We closed 2024 on a s

      2/26/25 4:05:00 PM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACAD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent

      - Composition of matter patent affirmed, provides protection into 2030 - Builds on recent ruling in favor of Acadia for formulation patent expiring in 2038 Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that the U.S. Court of Appeals for the Federal Circuit affirmed a decision issued by the U.S. District Court for the District of Delaware in December 2023 confirming validity of the NUPLAZID® (pimavanserin) '740 composition of matter patent. The affirmance came in Acadia's litigation against MSN Laboratories Pvt. Ltd. and MSN Pharmaceuticals, Inc. In its affirmance, the Appeals Court applied the precedent established in Allergan USA, Inc. v. MSN Laboratories Private Ltd., MS

      6/9/25 4:01:00 PM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025

      Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced it will host a R&D day in New York City to discuss its neurological and rare diseases pipeline on Wednesday, June 25, 2025 at 8:30 AM ET. The event will feature members of Acadia's management team and R&D organization, key opinion leaders (KOL) and members of the caregiver community. To register for the live webcast, please click here. A replay of Acadia's R&D Day will be available on the company's website, acadia.com, under the investors section for approximately 3 months following the event. About Acadia Pharmaceuticals Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been workin

      6/5/25 9:05:00 AM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acadia Pharmaceuticals to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

      Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 4:00 p.m. Eastern Time. A live webcast of Acadia's fireside chat will be accessible on the company's website, Acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation. About Acadia Pharmaceuticals Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed an

      5/29/25 4:05:00 PM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACAD
    Leadership Updates

    Live Leadership Updates

    See more
    • Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise

      Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced the appointment of Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise. In this role Allyson will be joining Acadia's commercial leadership team with a focus on maximizing the potential of DAYBUE® and preparing for future product launches as the Company expands its rare disease portfolio. "We are delighted to welcome Allyson to Acadia," said Catherine Owen Adams, Chief Executive Officer. "She brings a remarkable breadth of experience across U.S. and global sales and marketing roles, with a proven track record of delivering strong commercial results. Her leadership across therapeutic areas—including oncology

      5/27/25 4:05:00 PM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acadia Pharmaceuticals Set to Join S&P SmallCap 600

      NEW YORK, Dec. 30, 2024 /PRNewswire/ -- Acadia Pharmaceuticals Inc. (NASD: ACAD) will replace Independent Bank Group Inc. (NASD: IBTX) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, January 3, 2025. S&P MidCap 400 constituent SouthState Corp. (NYSE:SSB) is acquiring Independent Bank Group in a deal expected to close soon pending final conditions. Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector Jan 3, 2025 S&P SmallCap 600 Addition Acadia Pharmaceuticals ACAD Health Care Jan 3, 2025 S&P SmallCap 600 Deletion Independent Bank Group

      12/30/24 5:37:00 PM ET
      $ACAD
      $IBTX
      $SPGI
      $SSB
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Banks
      Finance
    • Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer

      – Seasoned commercial executive with more than 25 years pharmaceutical and biotech experience Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that Thomas Andrew Garner has been appointed Chief Commercial Officer, effective today. Mr. Garner will spearhead Acadia's commercial strategy and operations, driving the Company's plans for sustained growth and expansion of its product portfolio and pipeline across U.S. and international markets. Mr. Garner will report to Catherine Owen Adams, Acadia's CEO, and serve on the executive leadership team. "Tom is an accomplished commercial executive with a demonstrated history of driving brand growth across a wide range of therapeutic areas

      12/9/24 9:00:00 AM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACAD
    SEC Filings

    See more
    • SEC Form 8-K filed by ACADIA Pharmaceuticals Inc.

      8-K - ACADIA PHARMACEUTICALS INC (0001070494) (Filer)

      6/10/25 4:06:24 PM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by ACADIA Pharmaceuticals Inc.

      144 - ACADIA PHARMACEUTICALS INC (0001070494) (Subject)

      6/4/25 4:35:16 PM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by ACADIA Pharmaceuticals Inc.

      8-K - ACADIA PHARMACEUTICALS INC (0001070494) (Filer)

      5/29/25 4:06:35 PM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACAD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for NUPLAZID issued to ACADIA PHARMS INC

      Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-9) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 09/15/2023. Application Category: NDA, Application Number: 210793, Application Classification: Efficacy

      9/18/23 10:47:05 AM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for NUPLAZID issued to ACADIA PHARMS INC

      Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-12) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 09/15/2023. Application Category: NDA, Application Number: 207318, Application Classification: Efficacy

      9/18/23 10:40:05 AM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for DAYBUE issued to ACADIA PHARMS INC

      Submission status for ACADIA PHARMS INC's drug DAYBUE (ORIG-1) with active ingredient TROFINETIDE has changed to 'Approval' on 03/10/2023. Application Category: NDA, Application Number: 217026, Application Classification: Type 1 - New Molecular Entity

      3/13/23 10:37:07 AM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACAD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ACADIA Pharmaceuticals upgraded by Deutsche Bank with a new price target

      Deutsche Bank upgraded ACADIA Pharmaceuticals from Hold to Buy and set a new price target of $35.00

      5/21/25 8:39:09 AM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Deutsche Bank initiated coverage on ACADIA Pharmaceuticals with a new price target

      Deutsche Bank initiated coverage of ACADIA Pharmaceuticals with a rating of Hold and set a new price target of $22.00

      2/11/25 7:00:07 AM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ACADIA Pharmaceuticals downgraded by Guggenheim with a new price target

      Guggenheim downgraded ACADIA Pharmaceuticals from Buy to Neutral and set a new price target of $20.00 from $23.00 previously

      1/3/25 7:17:06 AM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACAD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ACADIA Pharmaceuticals Inc.

      SC 13G/A - ACADIA PHARMACEUTICALS INC (0001070494) (Subject)

      11/14/24 6:48:52 AM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by ACADIA Pharmaceuticals Inc.

      SC 13G - ACADIA PHARMACEUTICALS INC (0001070494) (Subject)

      2/14/24 7:08:13 AM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by ACADIA Pharmaceuticals Inc. (Amendment)

      SC 13G/A - ACADIA PHARMACEUTICALS INC (0001070494) (Subject)

      2/13/24 4:56:01 PM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACAD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Brege Laura sold $314,634 worth of shares (14,446 units at $21.78), decreasing direct ownership by 49% to 15,095 units (SEC Form 4)

      4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)

      6/5/25 6:01:14 PM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Daly James M converted options into 9,387 shares, increasing direct ownership by 38% to 34,041 units (SEC Form 4)

      4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)

      6/2/25 6:05:06 PM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ndu Adora converted options into 9,387 shares, increasing direct ownership by 61% to 24,801 units (SEC Form 4)

      4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)

      6/2/25 6:05:12 PM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care